Ono Pharmaceutical Signs an Exclusive License Agreement with Forty Seven to Develop and Commercialize 5F9 in Selected Asian Countries

Shots:

• Forty Seven to receive ~ $15.8M up front, ~$104M as development and commercial milestones and royalties on sales of 5F9 in selected territories and will retain WW rights of 5F9 including the US, EU and China
• Ono to get exclusive rights to develop and commercialize 5F9 as monothx./combination therapy for all therapeutic uses in Japan, South Korea, Taiwan and selected Southeast Asian countries and will participate in global clinical studies of 5F9 in selected territories
• 5F9 is mAb targeting CD47 and has received FDA’s FT designation for r/r DLBCL, FL, two forms of B-cell NHL and FDA & EMA’s ODD for AML

Click here to read full press release/ article | Ref: Globe NewsWire | Image: Forty Seven